Outcome of patients without any immunosuppressive therapy after renal allograft failure.
Continuation of low-dose maintenance immunosuppressive therapy in end-stage renal allografts (ESRAs) that are left in situ is controversial. We studied the outcome of 85 patients (mean age 33.3 +/- 13.4 and range of 12-56 years) on hemodialysis with ESRAs, and without immunosuppressive therapy in our center from July 1991 to July 2003. Twelve (14.1%) study patients underwent allograft nephrectomy within a mean interval of 44.5 months after graft failure. The rest of the patients remained stable without fever, hematuria, graft tenderness, or localized edema during a mean interval of 46.5 +/- 45.2 months of follow-up. These results are promising and suggest that maintenance immuno-suppressive therapy in patients with ESRAs and on dialysis may not be necessary to avoid allograft nephrectomy. Prospective studies are warranted to substantiate these results.
Naini
Afsoon Emami
AE
Department of Nephrology, Khorshid Hospital, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. af_emami@med.mui.ac.ir
Harandi
Ali Amini
AA
Daemi
Pooya
P
Kosari
Rozbeh
R
Gharavi
Manochehr
M
D000293:Adolescent; D000328:Adult; D002648:Child; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008875:Middle Aged; D009392:Nephrectomy; D006435:Renal Dialysis; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D017211:Treatment Failure
D007166:Immunosuppressive Agents